no interest from big pharma or not enough because our results are in the main part inadequate, pre clinical or half way through phase 1’s. They need to seriously hurry the fug up…. And efficacy must be evident in phase 1. Spare me the safety and tolerability is a success argument. They have designed efficacy in as a secondary end point and it is of critical importance to getting bought out or partnered or licenced before we run out of money.
the only head scratch is hervax. I rate it. It is phase 2 proven to lengthen life better than soc. I assume there might have been brinkmanship from imugene and they missed an early deal window as a result. Now they are in no hurry.
no interest from big pharma or not enough because our results...
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.2¢ |
Change
-0.003(3.53%) |
Mkt cap ! $600.2M | |||
| Open | High | Low | Value | Volume |
| 8.5¢ | 8.6¢ | 8.2¢ | $1.246M | 14.84M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 446526 | 8.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.3¢ | 535664 | 2 |
View Market Depth
| Last trade - 16.10pm 03/05/2024 (20 minute delay) ? |
|
|||||
|
Last
8.2¢ |
Change
-0.003 ( 2.38 %) |
||||
| Open | High | Low | Volume | ||
| 8.6¢ | 8.6¢ | 8.2¢ | 4518456 | ||
| Last updated 15.57pm 03/05/2024 ? | |||||
| IMU (ASX) Chart |